NGS results obtained from ascites of patients with pancreatic cancer showed that 33, 13, and 7% were positive for KRAS, TP53, and CDH1 mutations, respectively, whereas analysis of ascites samples from gastric cancer patients showed that 25, 12, and 13% were positive for KRAS, TP53, and APC mutations, respectively. This evidence concerns the gene KRAS and familial pancreatic carcinoma.